Papaverine Stock recalls

The FDA has published 1 recall involving Papaverine Stock since 2022. The latest was reported on 9 Nov 2022. Most were for sterility. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.

Total recalls1since 2022

Last 12 months0reported

Class I00% of total

Ongoing1latest 9 Nov 2022

Recalls per month, last 24 months

click a bar for that month

0Nov '24 0 0 0Feb 0 0 0May 0 0 0Aug 0 0 0Nov 0 0 0Feb 0 0 0May 0 0 0Aug 0 0

Severity split

Class I 0 0%Class II 1 100%Class III 0 0%

Why papaverine stock is recalled

Sterility1100%

Companies

Pharmacy Plus1100%

By year

20221100%

Ongoing papaverine stock recalls

1 active

Reported	Class	Recall	Company	Reason	Where
9 Nov 2022Drug	CLASS II	Papaverine HCL Stock Solution 30MG/ML Solution vial recalled	Pharmacy Plus	Sterility	4 states

All papaverine stock recalls, newest first

1 total

Reported	Class	Recall	Company	Reason	Where
9 Nov 2022Drug	CLASS II	Papaverine HCL Stock Solution 30MG/ML Solution vial recalled	Pharmacy Plus	Sterility	4 states

Should you stop taking Papaverine Stock?

Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.